189 related articles for article (PubMed ID: 33875750)
1. The effect of sirolimus on angiomyolipoma is determined by decrease of fat-poor compartments and includes striking reduction of vascular structures.
Watanabe EH; Coelho FMA; Filho HL; Balbo BEP; Neves PDMM; Franzin FM; Yamauchi FI; Onuchic LF
Sci Rep; 2021 Apr; 11(1):8493. PubMed ID: 33875750
[TBL] [Abstract][Full Text] [Related]
2. Sirolimus therapy for angiomyolipoma in tuberous sclerosis and sporadic lymphangioleiomyomatosis: a phase 2 trial.
Davies DM; de Vries PJ; Johnson SR; McCartney DL; Cox JA; Serra AL; Watson PC; Howe CJ; Doyle T; Pointon K; Cross JJ; Tattersfield AE; Kingswood JC; Sampson JR
Clin Cancer Res; 2011 Jun; 17(12):4071-81. PubMed ID: 21525172
[TBL] [Abstract][Full Text] [Related]
3. Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis.
Bissler JJ; McCormack FX; Young LR; Elwing JM; Chuck G; Leonard JM; Schmithorst VJ; Laor T; Brody AS; Bean J; Salisbury S; Franz DN
N Engl J Med; 2008 Jan; 358(2):140-51. PubMed ID: 18184959
[TBL] [Abstract][Full Text] [Related]
4. Angiomyolipoma rebound tumor growth after discontinuation of everolimus in patients with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis.
Bissler JJ; Nonomura N; Budde K; Zonnenberg BA; Fischereder M; Voi M; Louveau AL; Herbst F; Bebin EM; Curatolo P; Zonta A; Belousova E
PLoS One; 2018; 13(9):e0201005. PubMed ID: 30192751
[TBL] [Abstract][Full Text] [Related]
5. Sirolimus and tuberous sclerosis-associated renal angiomyolipomas.
Krischock L; Beach R; Taylor J
Arch Dis Child; 2010 May; 95(5):391-2. PubMed ID: 20457704
[TBL] [Abstract][Full Text] [Related]
6. CT characteristics predict the response to everolimus or sirolimus of renal angiomyolipomas in patients with tuberous sclerosis complex.
Wang W; Guo H; Shi B; Sun H; Li H; Zhang Y; Cai Y
Int Urol Nephrol; 2019 Apr; 51(4):671-676. PubMed ID: 30756282
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of sirolimus for renal angiomyolipoma in patients with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis: a systematic review.
Peng ZF; Yang L; Wang TT; Han P; Liu ZH; Wei Q
J Urol; 2014 Nov; 192(5):1424-30. PubMed ID: 24813310
[TBL] [Abstract][Full Text] [Related]
8. Everolimus for renal angiomyolipoma in patients with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis: extension of a randomized controlled trial.
Bissler JJ; Kingswood JC; Radzikowska E; Zonnenberg BA; Frost M; Belousova E; Sauter M; Nonomura N; Brakemeier S; de Vries PJ; Berkowitz N; Miao S; Segal S; Peyrard S; Budde K
Nephrol Dial Transplant; 2016 Jan; 31(1):111-9. PubMed ID: 26156073
[TBL] [Abstract][Full Text] [Related]
9. Lymphangioleiomyomatosis.
Johnson SR; Taveira-DaSilva AM; Moss J
Clin Chest Med; 2016 Sep; 37(3):389-403. PubMed ID: 27514586
[TBL] [Abstract][Full Text] [Related]
10. Regression of renal angiomyolipomas with oral rapamycin therapy in a patient with tuberous sclerosis complex disease.
Torun D; Micozkadioglu H; Gedikoglu M; Ozelsancak R; Tekkarismaz N
Saudi J Kidney Dis Transpl; 2019; 30(2):545-548. PubMed ID: 31031395
[TBL] [Abstract][Full Text] [Related]
11. Reduction in size of renal angiomyolipoma after treatment with everolimus in lung transplantation due to lymphangioleiomyomatosis.
Bujalance-Cabrera C; Vaquero-Barrios JM; Redel-Montero J; Caballero-Ballesteros L; Requejo-Jiménez A; Santos-Luna F
Arch Bronconeumol; 2012 Dec; 48(12):479-81. PubMed ID: 22444789
[TBL] [Abstract][Full Text] [Related]
12. Multicenter phase 2 trial of sirolimus for tuberous sclerosis: kidney angiomyolipomas and other tumors regress and VEGF- D levels decrease.
Dabora SL; Franz DN; Ashwal S; Sagalowsky A; DiMario FJ; Miles D; Cutler D; Krueger D; Uppot RN; Rabenou R; Camposano S; Paolini J; Fennessy F; Lee N; Woodrum C; Manola J; Garber J; Thiele EA
PLoS One; 2011; 6(9):e23379. PubMed ID: 21915260
[TBL] [Abstract][Full Text] [Related]
13. Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial.
Bissler JJ; Kingswood JC; Radzikowska E; Zonnenberg BA; Frost M; Belousova E; Sauter M; Nonomura N; Brakemeier S; de Vries PJ; Whittemore VH; Chen D; Sahmoud T; Shah G; Lincy J; Lebwohl D; Budde K
Lancet; 2013 Mar; 381(9869):817-24. PubMed ID: 23312829
[TBL] [Abstract][Full Text] [Related]
14. Similar trends in serum VEGF-D levels and kidney angiomyolipoma responses with longer duration sirolimus treatment in adults with tuberous sclerosis.
Malinowska IA; Lee N; Kumar V; Thiele EA; Franz DN; Ashwal S; Sagalowsky A; Dimario FJ; Cutler D; Krueger D; Camposano S; Paolini J; Dabora SL
PLoS One; 2013; 8(2):e56199. PubMed ID: 23437092
[TBL] [Abstract][Full Text] [Related]
15. Antitumoral activity of rapamycin in renal angiomyolipoma associated with tuberous sclerosis complex.
Wienecke R; Fackler I; Linsenmaier U; Mayer K; Licht T; Kretzler M
Am J Kidney Dis; 2006 Sep; 48(3):e27-9. PubMed ID: 16931204
[TBL] [Abstract][Full Text] [Related]
16. The efficacy of cannabidiol on renal angiomyolipoma and subependymal giant cell tumor volume in tuberous sclerosis complex.
Barnett JR; Grinspoon RA; Harisinghani M; Caruso PA; Thiele EA
J Clin Neurosci; 2020 Jul; 77():85-88. PubMed ID: 32409220
[TBL] [Abstract][Full Text] [Related]
17. Effects of rapamycin on angiomyolipomas in patients with tuberous sclerosis.
Cabrera López C; Martí T; Catalá V; Torres F; Mateu S; Ballarín Castán J; Torra Balcells R
Nefrologia; 2011; 31(3):292-8. PubMed ID: 21629335
[TBL] [Abstract][Full Text] [Related]
18. Low-dose rapamycin reduces kidney volume angiomyolipomas and prevents the loss of renal function in a patient with tuberous sclerosis complex.
Peces R; Peces C; Cuesta-López E; Pérez-Dueñas V; Vega-Cabrera C; Azorín S; Selgas R
Nephrol Dial Transplant; 2010 Nov; 25(11):3787-91. PubMed ID: 20663789
[TBL] [Abstract][Full Text] [Related]
19. Everolimus long-term use in patients with tuberous sclerosis complex: Four-year update of the EXIST-2 study.
Bissler JJ; Kingswood JC; Radzikowska E; Zonnenberg BA; Belousova E; Frost MD; Sauter M; Brakemeier S; de Vries PJ; Berkowitz N; Voi M; Peyrard S; Budde K
PLoS One; 2017; 12(8):e0180939. PubMed ID: 28792952
[TBL] [Abstract][Full Text] [Related]
20. Clinical and molecular insights into tuberous sclerosis complex renal disease.
Siroky BJ; Yin H; Bissler JJ
Pediatr Nephrol; 2011 Jun; 26(6):839-52. PubMed ID: 21152937
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
